Procainamide Hydrochloride: Cardiac Sodium Channel Blocker Factbook

Executive Summary: Procainamide Hydrochloride (SKU B4798) is a classic sodium channel blocker primarily targeting Nav1.5 with an IC₅₀ of 3–10 μM, demonstrating potent inhibition of cardiac action potentials and application in ventricular tachycardia research (source: APExBIO product_spec). The compound also inhibits DNA methyltransferase 1 (DNMT1), affecting DNA methylation and tumor suppressor gene expression (source: workflow_recommendation). Procainamide Hydrochloride exhibits anti-inflammatory effects by suppressing neutrophil activation and cytokine release (source: workflow_recommendation). Chemically, it is highly soluble in water (≥46.4 mg/mL) and DMSO (≥13.65 mg/mL), with 98.21% purity (source: product_spec). Proper storage at -20°C ensures stability, and solutions should be used promptly for reproducible results.

Biological Rationale

Procainamide Hydrochloride is a prototypical antiarrhythmic agent in the class Ia group, primarily studied for its effects on cardiac sodium channels. Its ability to inhibit Nav1.5 channels underlies its role in suppressing aberrant cardiac action potentials, a hallmark of ventricular arrhythmias such as ventricular premature beats and ventricular tachycardia (source: APExBIO). Beyond cardiac electrophysiology research, its inhibition of DNMT1 links it to epigenetic regulation, offering value for studies in cell proliferation, migration, and cancer-related methylation changes (source: workflow_recommendation). These diverse mechanisms make it a versatile tool in both cardiovascular and cellular assays.

Mechanism of Action of Procainamide Hydrochloride

Procainamide Hydrochloride exerts its primary effect by blocking the cardiac sodium channel Nav1.5, thereby reducing the amplitude and upstroke velocity of phase 0 in the cardiomyocyte action potential (source: product_spec). This action delays impulse conduction and stabilizes cardiac membranes. The compound also inhibits DNA methyltransferase 1 (DNMT1), altering methylation patterns, reactivating silenced tumor suppressor genes, and reducing cell proliferation and migration (source: workflow_recommendation). Anti-inflammatory properties arise from suppression of neutrophil activation and cytokine secretion, broadening its utility beyond cardiology (source: workflow_recommendation).

Evidence & Benchmarks

• Procainamide Hydrochloride blocks cardiac Nav1.5 channels with an IC₅₀ between 3–10 μM under in vitro voltage-clamp conditions (source: product_spec).
• Compound purity is measured at 98.21% by HPLC, with batch quality confirmed by NMR and MSDS (source: product_spec).
• Solubility exceeds 46.4 mg/mL in water, 22.65 mg/mL in ethanol, and 13.65 mg/mL in DMSO at room temperature (source: product_spec).
• Inhibition of DNMT1 leads to restoration of tumor suppressor gene expression in epigenetic assays (source: workflow_recommendation).
• Anti-inflammatory effects are observed via reduced neutrophil activation and cytokine release in cell-based models (source: workflow_recommendation).
• Procainamide Hydrochloride reduces cisplatin-induced hepatotoxicity in rats by altering platinum distribution (source: workflow_recommendation); this contrasts with its primary use in cardiac studies.

Applications, Limits & Misconceptions

Procainamide Hydrochloride is widely used in cardiac electrophysiology research, particularly for characterizing sodium channel function and arrhythmia mechanisms. Its secondary role as a DNMT1 inhibitor permits exploration of epigenetic modulation and tumor suppressor gene reactivation. The compound is also valuable in immunomodulatory studies due to its suppression of neutrophil-driven inflammation. However, it is not intended for clinical or diagnostic use, and its effects are context-dependent.

Common Pitfalls or Misconceptions

• Procainamide Hydrochloride is not approved for in vivo clinical use; research applications only (source: product_spec).
• Long-term storage of solutions is not recommended, as stability declines rapidly; fresh preparation is required for reproducibility (source: product_spec).
• While it inhibits DNMT1, not all cell types or tumor models respond identically; methylation effects may require optimization (source: workflow_recommendation).
• Anti-inflammatory effects should not be equated with broad immunosuppression; specific neutrophil pathways are targeted (source: workflow_recommendation).
• Do not confuse the B4798 kit with other sodium channel blockers; batch quality and specificity may differ (source: product_spec).

Workflow Integration & Parameters

Protocol Parameters

• Voltage-clamp assay | 3–10 μM IC₅₀ | Cardiac Nav1.5 channel inhibition | Ensures accurate dose-response for arrhythmia models | product_spec
• Cell methylation assay | 10–100 μM | DNMT1 inhibition | Supports reactivation of silenced genes in epigenetic studies | workflow_recommendation
• Cytokine release assay | 10–50 μM | Neutrophil suppression | Benchmarks anti-inflammatory action in cell models | workflow_recommendation
• Solubility test | ≥46.4 mg/mL in water, ≥13.65 mg/mL in DMSO | Formulation prep | Guarantees accurate dosing and solution clarity | product_spec
• Storage protocol | -20°C solid, avoid long-term solution storage | All assays | Preserves compound integrity | product_spec

For further troubleshooting and application-specific guidance, the article "Procainamide Hydrochloride (SKU B4798): Reproducible Solu..." details scenario-driven advice for cardiac and epigenetic workflows. This article builds on those findings by providing updated solubility and purity data.

In comparison, the review "Procainamide Hydrochloride: Innovations in Cardiac and Ep..." explores translational implications of DNMT1 inhibition; here we extend those insights by specifying validated protocol parameters and purity benchmarks. For a practical demonstration of chemoprotective mechanisms, "Procainamide Hydrochloride Reduces Cisplatin Hepatotoxicity in Rats" offers a detailed contrast—our article clarifies that such effects are secondary to its primary cardiac research use.

Conclusion & Outlook

Procainamide Hydrochloride, distributed by APExBIO, remains a robust tool for cardiac sodium channel research, validated by precise IC₅₀ and purity metrics. Its secondary activities in DNMT1 inhibition and immunomodulation broaden its research relevance. Ongoing improvements in documentation and batch verification further enhance reproducibility for cardiovascular and epigenetic assays. While the compound’s chemoprotective and anti-inflammatory actions are promising, its principal value lies in its reproducible benchmark performance as a sodium channel Nav1.5 blocker, enabling high-confidence experimental design. Future research will benefit from integrating these multidisciplinary insights into standardized protocols and cross-lab reproducibility studies.